Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial

By sjmartinez • September 10, 2024

Evering TH, Moser C, Jilg N, Ritz J, Wohl DA, Li JZ, Margolis D, Javan AC, Eron JJ, Currier JS, Daar ES, Smith DM, Hughes MD, Chew KW; ACTIV-2/A5401 Study Team. Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial. EClinicalMedicine. 2024 Aug 16;75:102787. doi: 10.1016/j.eclinm.2024.102787. PMID: 39252866; PMCID: PMC11381616.

Tags: Clinical Trial, covid-19, Harbor UCLA, Infectious Diseases, long COVID, Monoclonal antibodies, outpatient treatment, PASC, Post COVID conditions, Post-acute sequelae of SARS-CoV-2 infection, Publications

Less is More: A Cost and Environmental Waste Analysis in Nonadherence to Antibiotic Prophylaxis Guidelines in Clean Ambulatory Surgical Procedures

Sandigo-Saballos I, Montero S, Lee P, Lee H, Chen KT. Less is More: A Cost and Environmental Waste Analysis in Nonadherence to Antibiotic Prophylaxis Guidelines[...]

Topological Data Analysis in the Assessment of Coronary Atherosclerosis: A Comprehensive Narrative Review

Singh Y, Hathaway QA, Farrelly C, Budoff MJ, Erickson B, Collins JD, Blaha MJ, Leiner T, Lopez-Jimenez F, Rozenblit J, Sarkar D, Carlsson G. Topological[...]

Coronary Artery Bypass Grafting Is Rarely Done in the Acute Care of ST-elevation Myocardial Infarction Patients Treated by Emergency Medical Services

Toy J, Lauer C, Kaji AH, Thomas JL, Megowan N, Bosson N, Gausche-Hill M, Dhawan P, Kloner RA, Rasnake S, French W, Schlesinger S. Coronary[...]